En
The Young Scientists Network (YSN) of the European Federation of Medicinal Chemistry and Chemical Biology (EFMC) decided to launch MedChemBioOnline, a series of webinars which will mix science, soft-skills trainings and round table discussions.
Organized every two months on a free-to-attend basis, the 2,5 hours webinars aims to meet the current needs of our scientific community to continue interacting and sharing ideas and innovation, as well as providing early career scientists with opportunities to listen to outstanding scientists and expand their knowledge.
What do you want to see next?
We are really keen to hear your feedback, receive ideas for soft-skill trainings or speakers' suggestions.
Please get in touch with us:
TOPIC: PROTAC and Small Molecules Development
Chairwoman
Dr Chiara Borsari (University of Basel, Switzerland)
Moderator
Mr Matic Proj (University of Ljubljana, Slovenia)
PROGRAMME:
The event is free and open to all thanks to the generous support of Symeres.
Symeres is the leading mid-sized European Contract Research Organization for your drug discovery and development needs. With over 500 scientists, we offer best-in-class solutions from early-stage hit finding to the delivery of your early clinical drug substance API, for small- to medium-sized molecules.
TOPIC: Artificial Intelligence applied to Medicinal Chemistry
Chairwoman
Dr Kristina Goncharenko (Spirochem, Switzerland)
Moderator
Dr Filipa Ramilo Gomes (Instituto Superior Técnico, University of Lisbon, Portugal)
PROGRAMME:
The event was generously sponsored by Schrödinger.
To improve human health and quality of life by transforming the way therapeutics and materials are discovered.
RECORDING AVAILABLE: By clicking on "video" next to the title of each talk, you will be directed to the corresponding recording available on the EFMC YouTube Channel.
PROGRAMME:
Chairwoman
Dr Filipa Ramilo Gomes (Instituto Superior Técnico, University of Lisbon, Portugal)
Moderator
Dr Leire Iralde Lorente (University of Siena, Italy)
RECORDING AVAILABLE: By clicking on "video" next to the title of each talk, you will be directed to the corresponding recording available on the EFMC YouTube Channel.
PROGRAMME:
Chairwoman
Dr Kristina Goncharenko (Spirochem, Switzerland)
Moderator
Mrs Caroline Lanthier (University of Caen Normandy, France)
Synple Chem is a developer of new organic synthesis technologies. Our automated capsule-based synthesizers work analogously to capsule coffee makers - simply add the starting material and a commercially available, single-use, disposable reagent capsule, then with a single touch of a button, the product is generated, isolated and purified!
RECORDING AVAILABLE: By clicking on "video" next to the title of each talk, you will be directed to the corresponding recording available on the EFMC YouTube Channel.
PROGRAMME:
Chairman
Dr Clemens Zwergel (Sapienza University of Rome, Italy)
Moderator
Mr Matic Proj (University of Ljubljana, Slovenia)
MercachemSyncom is the leading mid-sized European drug-discovery CRO for solving your chemistry challenges, from small to medium-sized molecule hits, to the first GMP batches of identified clinical candidates. We blend vast scientific knowledge with inventiveness to make great leaps on your behalf. We go further to unlock new potential.
Recording/Presentations available: By clicking on the title of each talk, you will be directed to the corresponding recording available on the EFMC YouTube Channel, or access the slide deck when a recording is not available.
PROGRAMME:
Chairman
Dr Michele Mari (Università degli Studi di Urbino Carlo Bo, Italy)
Moderator
Ms Pauline Zipfel (University of Caen Normandy, France)
The event was generously sponsored by WuXi AppTec.
Established in December 2000, WuXi AppTec provides a broad portfolio of R&D and manufacturing services to advance discoveries and deliver groundbreaking treatments to patients. WuXi AppTec HitS Unit provides a one-stop Target-to-Hit services that enable companies in the pharmaceuticals, biotech and academics worldwide to seek premium drug discovery. With industry-leading capabilities such as protein science, biophysics, DNA-encoded library technology, and structure-based drug design, HitS is committed to drive toward the realization of the vision that every drug can be made and every disease can be treated.
